Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic‐phase chronic myeloid leukemia based on early achievement of deep molecular response (MR(4.5)):...

por Nishiwaki, Kaichi, Sugimoto, Kei‐ji, Tamaki, Shigehisa, Hisatake, Junichi, Yokoyama, Hisayuki, Igarashi, Tadahiko, Shinagawa, Atsushi, Sugawara, Takeaki, Hara, Satoru, Fujikawa, Kazuhisa, Shimizu, Seiichi, Yujiri, Toshiaki, Tojo, Arinobu, Wakita, Hisashi
Publicado 2020

Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan

por Takahashi, Naoto, Nishiwaki, Kaichi, Nakaseko, Chiaki, Aotsuka, Nobuyuki, Sano, Koji, Ohwada, Chikako, Kuroki, Jun, Kimura, Hideo, Tokuhira, Michihide, Mitani, Kinuko, Fujikawa, Kazuhisa, Iwase, Osamu, Ohishi, Kohshi, Kimura, Fumihiko, Fukuda, Tetsuya, Tanosaki, Sakae, Takahashi, Saori, Kameoka, Yoshihiro, Nishikawa, Hiroyoshi, Wakita, Hisashi
Publicado 2018

Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response

por Okamoto, Yuji, Hirano, Mitsuhito, Morino, Kai, Kajita, Masashi K., Nakaoka, Shinji, Tsuda, Mayuko, Sugimoto, Kei-ji, Tamaki, Shigehisa, Hisatake, Junichi, Yokoyama, Hisayuki, Igarashi, Tadahiko, Shinagawa, Atsushi, Sugawara, Takeaki, Hara, Satoru, Fujikawa, Kazuhisa, Shimizu, Seiichi, Yujiri, Toshiaki, Wakita, Hisashi, Nishiwaki, Kaichi, Tojo, Arinobu, Aihara, Kazuyuki
Publicado 2022